SEC Form 4 · accession 0001209191-15-004432

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 14, 2015

Accepted (ET)

Jan 15, 2015 · 4:46 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jan 14, 2015	M	4,800	$10.41	A	343,695	D
Common Stock	Jan 14, 2015	M	1,300	$17.16	A	344,995	D
Common Stock	Jan 14, 2015	M	4,400	$35.64	A	349,395	D
Common Stock^F2,F3	Jan 14, 2015	S	2,800	$119.72	D	346,595	D
Common Stock^F3,F4	Jan 14, 2015	S	7,500	$120.30	D	339,095	D
Common Stock	Jan 14, 2015	S	200	$121.00	D	338,895	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F5	holding	—	—		—	172,589	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$10.41	Jan 14, 2015	M	4,800	D	—	Feb 2, 2015	Common Stock	4,800	9,788	D
Stock Option (right to buy)^F6	$17.16	Jan 14, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	34,300	D
Stock Option (right to buy)^F6	$35.64	Jan 14, 2015	M	4,400	D	—	Feb 1, 2016	Common Stock	4,400	538,400	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $119.72 (range $118.98 to $119.96).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $120.30 (range $119.98 to $120.83).
F5Common stock held in grantor retained annuity trusts.
F6Fully vested.